Dr. Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
How long-term intravitreal steroid technology fits into a modern clinic.
Minimizing clinic visits, maximizing use of imaging modalities are key
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Rather than speculating in a vacuum about the future of remote monitoring in ophthalmology, it is better to explore how other specialties in medicine adopted and integrated remote monitoring into their care plan frameworks.
A retina specialist discusses impressions and key take away points from patient case.
Dr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.
Nathan Steinle, MD; Adrienne Scott, MD; Carl Regillo, MD, FACS, FASRS; and Prethy Rao, MD, MPH, share final thoughts on the changing treatment landscape of neovascular AMD and DME.
In-person and virtual trainings, coupled with the support of local product representatives, are the best ways to ensure retina specialists are set up for success.
Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.
The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.
Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.
Safety data on non-clinician-led services have shown a low complication rate
Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.
Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Physicians can discover, diagnose, document, treat diseases that might go undetected
Chronic cases can be difficult for retina specialists; treatment is satisfying.
This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.
Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.
In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Current options, challenges in developing novel therapies.